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INTRODUCTION:  Skin  necrosis  is  a rare  complication  of foam  sclerotherapy,  a common  form  of  treatment
for varicose  veins.
PRESENTATION OF  CASE:  Both  patients  presented  to the  outpatient  clinic  within  2–14  days  after  foam
sclerotherapy  with  Aethoxysklerol® 1%,  with  severe  soft  tissue  and  skin  necrosis.  Further  aggressive
treatment  of the  ulcer  was  required  to  resolve  the  necrosis,  resulting  in  marked  residual  scar  and  well
granulated  leg  ulcer  respectively.
DISCUSSION:  Foam  sclerotherapy  is  a common  and  usually  well-tolerated  treatment  modality  for  varicose
veins. The  aetiology  of  skin  necrosis  is  conventionally  related  to extravasation  of sclerosant.  In  order  tokin necrosis
ebridement
lcer
minimise  the  risk  of  necrosis,  the  lowest  concentration  and  lowest  volume  of sclerosant  necessary  to
achieve  adequate  treatment  of  the  target  vein  should  be used.
CONCLUSION:  We  would  like  to emphasise  that  whilst  skin  and  soft  tissue  necrosis  is  a rare  complication
of  foam  sclerotherapy,  it is  a complication  that  is highly  disﬁguring  and  requires  aggressive  treatment.
As  such,  it  should  be  adequately  discussed  with  the  patient  prior to  obtaining  informed  consent.
© 2016  The  Author(s).  Published  by  Elsevier  Ltd  on behalf  of IJS  Publishing  Group  Ltd.  This  is  an  open
he  CCaccess  article  under  t
. Introduction
Ultrasound-guided foam sclerotherapy involves injecting a
hemical agent (a sclerosant) to induce blood vessel scarring and
losure. In foam sclerotherapy, air is mixed with the liquid scle-
osant to create foam. When this is injected into the varicose vein
under ultrasound guidance), it displaces the blood within the vein
nd ﬁlls the vein, causing the vein to spasm and scar. Foam scle-
otherapy has a good success rate, with 80–90% of veins remaining
losed after 3 years. As reported in the consensus document of the
merican Society of Dermatologic Surgery, the advantage of foam
s that the sclerosing power of the solution is increased three-fold,
hile the toxicity is decreased four-fold [1]. Reported complica-
ions include bleeding, bruising, thrombophlebitis, infection at the
njection site, deep vein thrombosis, pulmonary embolism, skin
taining, and skin necrosis [2]. Whilst skin necrosis is rare, with a
eported incidence of 0.2–1.2% [1], it is a complication that is highly
isﬁguring and requires aggressive treatment. Here, we report two
ases of patients who experienced atypical extensive skin necrosis
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following sclerotherapy using liquid Aethoxysklerol® 1% (polido-
canol, laureth-9).
2. Case report
1st Patient was a 32-year-old woman who presented to the
vascular outpatient clinic in June 2011 for treatment of some promi-
nent varicosities in her right leg. The patients’ history of mild
Von Willebrand’s disease (vWD type IIA) resulted in varicosities
secondary to an arterio-venous malformation. Von Willebrand’s
disease was conﬁrmed by the measurement of the ristocetin cofac-
tor (RCoF) activity below 30 IU/d. She had right leg ulceration after
minor trauma in the past, which left her with marked scarring.
In July 2014, she re-presented with a 4 mm subcutaneous
lump on her right anterior shin. After review, the lump was
deemed secondary to thrombophlebitis and managed conserva-
tively. She re-presented a few weeks later with varicosities that
were secondary to her well-known AV malformation, conﬁrmed
by duplex scanning. She was offered foam sclerotherapy of the
varicosities and underwent treatment with an unknown dosage
of Aethoxysklerol® 1% (polidocanol, laureth-9) in September 2014
in a private clinic. Two days following treatment, she presented
to the wound clinic with an area of tissue necrosis on the medial
aspect of the right knee (Fig. 1). On clinical and duplex examina-
tion, it was  established that there was no arterial compromise and a
mepilex® border dressing (Mölnlycke Health Care AB, Gothenburg,
Group Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Fig. 1. Patient 1: area of tissue necrosis on the medial aspect of the right knee that
appear two  days following Aethoxysklerol® 1% foam sclerotherapy.
Fig. 2. Patient 1: picture showing that the necrotic areas increasing in size and began
to  demarcate and lift, without any clinical evidence of infection.
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Fig. 4. Patient 2: the ulcer developed 4 weeks after treatment of an incompetent
short saphenous vein and lateral aspect varicosities with Aethoxysklerol® 1% foam
sclerotherapy.ig. 3. Patient 1: ﬁve months post-treatment, the ulcers healed with marked resid-
al scarring.
weden) was applied. Over the subsequent months, the necrotic
reas increased in size and began to demarcate and lift, without
nfection (Fig. 2). Five months post-treatment, the ulcers healed
ith marked residual scarring (Fig. 3). On discharge from the
ound clinic, the patient was advised to continue moisturising the
rea to improve scarring.Fig. 5. Patient 2: large lateral sloughy left leg ulcer (11 × 4 cm) in December 2015.
2nd Patient was  a 69-year-old woman who  had suffered from
chronic venous disease for 10 years and presented at a private clinic
with leg oedema (CEAP class C3). The ulcer developed 4 weeks
after treatment of an incompetent short saphenous vein and lateral
aspect varicosities with Aethoxysklerol® 1% foam sclerotherapy
(Fig. 4). She was  admitted to the vascular ward in December 2015
after developing a large lateral sloughy left leg ulcer 11 × 4 cm
(Fig. 5). The left leg arterial duplex scan was normal and the results
from the microbiology samples were clear from infection. We
decided to proceed with debridement of the ulcer. She underwent
4 sessions of out patient low-frequency ultrasound debridement
(LFUD) using the SONOCA-185® Machine (MediGroup Australia Pty
Ltd, Melbourne, Australia). EMLA® cream (Eutectic Mixture of Local
Anaesthetics, AstraZeneca Pty Ltd, North Ryde, NSW, Australia)
with intrasite conformable was used 45–60 min  prior to each of
the LFUD treatments for pain control during the procedure.
Due to the size of the wound and the amount of devitalised tis-
sue, the initial LFUD treatment was  55 min in duration and the hoof
sonotrobe head was chosen for the directional spray. Patient pain
was minimal; hence the amplitude was set to a maximum effect of
100% for debridement with the normal saline ﬂow (lavage) set at
20%.
The second LFUD treatment was  45 min  in duration, using the
hoof sonotrobe head with concurrent suction. The amplitude was
decreased to 80% and the saline ﬂow was increased to 40% due to
the patient experiencing moderate pain. The third LFUD treatment
was 30 min  in duration, with simultaneous suction (with an ampli-
tude of 100%) and ﬂow adjusted to 40% according to the patient’s
tolerance. The ﬁnal LFUD treatment was 20 min in duration using
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sig. 6. Patient 2: smoother wound surface with healthy granulation tissue after 4
essions of out patient LFUD using the SONOCA-185® Machine (MediGroup Australia
ty Ltd, Melbourne, Australia).
he hoof sonotrobe head with amplitude of 80% and a ﬂow of 25%,
hich had been adjusted to the patient’s pain tolerance.
The debridement achieved a satisfactory outcome and the ulcer
as therefore managed with mepitel® dressing (Mölnlycke Health
are AB, Gothenburg, Sweden). On examination at the vascular
ound clinic in June 2016, there was a smoother wound surface
ith healthy granulation tissue (Fig. 6).
Foam sclerotherapy with Aethoxysklerol was  used in both
atients. This is a sterile solution of laureth-9 available in four
trengths, 0.5%, 1%, 2%, and 3%, buffered to pH 6.5–8.0. The excip-
ents in Aethoxysklerol are ethanol, sodium phosphate-dibasic
ihydrate, potassium phosphate monobasic, and water for injec-
ions. Foam is created with a 3-way stopcock and 2 syringes, one
oaded with a volume of room air and other with the volume of
etergent sclerosant. The air solution is passed quickly 10–20 times
etween the two syringes, which allows for rapid agitation and
oam creation [3].
. Discussion
Foam sclerotherapy is a common treatment modality for vari-
ose veins, which can be performed in the outpatient setting and
s well tolerated. Complications [4] of a generalized or localized
ature include anaphylactic/anaphylactoid reactions (very rare),
eep vein thrombosis (1–3%), stroke (0.01%), superﬁcial venous
hrombosis (4.4%), tissue necrosis (0.2–1.2%) [2], oedema (0.5%),
nd nerve damage (0.2%) [4]. Cosmetic complications include
elangiectatic matting (15–24%) and pigmentation (10–30%) [4,5].
There are different etiological factors of ulceration post scle-
otherapy, including operator, patient, and drug-dependent factors
6–9]. Operator-dependent factors include inadvertent intra-
rterial or arteriolar injection (microsclerotherapy) and excessive
njection pressure into the superﬁcial veins, which may  cause ret-
ograde ﬂow of sclerosant into the arterial capillary vasculature.
atient dependent factors include, smoking, vasculitis [Henoch-
chonlein, Erythema nodosum, Polyarteritis nodosa, Temporal
giant cell) arteritis, Takayasu’s arteritis, Wegener’s granulomato-
is], and arteriovenous malformation. In addition, some ulceration
an result from unknown factors. Foam can be used for spider veins,
ut there can be excessive inﬂammation with treatment of ves-
els of this size. Foam is more commonly used for reticular size
nd larger veins, as in the case of patient 1 [10]. Drug dependent
actors include a high concentration of Aethoxysklerol solution or
he use of undiluted solutions. Animal studies have also demon-
trated that higher sclerosant strength and viscosity and vessel sizePEN  ACCESS
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are implicated [11]. Intra-arteriolar injection leads to more severe
necrosis secondary to tissue ischemia. Foam treatment of telang-
iectasia has also been linked to skin damage, presumably secondary
to increased chance of extravasation.
Ultrasound-guided foam sclerotherapy is an effective treatment
adjunct for nonvisible subcutaneous varicosities and perforator
veins [10]. Following injection, the skin may blanch or become
erythematous and pain is normally a feature. Dermal loss usu-
ally occurs more than 24 h later. In order to minimise the risk of
necrosis, the lowest concentration and lowest volume of sclerosant
necessary to achieve adequate treatment of the target vein should
be used. Hyaluronidase is an enzyme that causes rapid dispersal of
extravasated solution and therefore its use can limit tissue dam-
age, if injected within 60 min  [11–13]. If intra-arterial injection is
suspected, topical nitroglycerine can also be used to produce local
vasodilation [13,14].
Dressings are the mainstay of treatment, with regular clinical
reviews. Wounds can be debrided surgically if necrotic tissue is
present, particularly if there is evidence of infection. Compres-
sion bandaging may  also be used, as with uncomplicated venous
ulceration. Ulceration can be prolonged, taking up to 6 months to
completely heal and often leaving residual scarring.
4. Conclusion
Although skin necrosis is a rare complication of foam sclerother-
apy, it is one that can be extremely disﬁguring. Therefore, it must be
discussed when consent is obtained from the patient prior to this
frequent procedure. The cases presented here highlight extreme
ulceration post-sclerotherapy. Although rare, it does occur, and the
resulting treatment consists of aggressive wound care, debride-
ment, and possible skin grafts.
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